Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Keyur Patel

Showing results (231-240 of 357) with videos related to

Pageof 36
Sort By:
Gastroenterology|July 13, 2010
An IL28B polymorphism determines treatment response of hepatitis C virus genotype 2 or 3 patients who do not achieve a rapid virologic responseAlessandra Mangia, Alexander J Thompson, Rosanna Santoro, et al.
International Journal of Cardiology|January 3, 2017
Depression and chest pain in patients with coronary artery diseaseSalim S Hayek, Yi-An Ko, Mosaab Awad, et al.
Advances in Wound Care|February 12, 2025
An Open-Label, Interventional, Prospective, Real-World Evidence Study to Evaluate a Multimodal Wound Matrix in Patients with Refractory WoundsYadwinder Dhillon, Gerit Mulder, Keyur Patel, et al.
Aging|September 4, 2023
Availability of living donor optimizes timing of liver transplant in high-risk waitlisted cirrhosis patientsFakhar Ali Qazi Arisar, Shiyi Chen, Catherine Chen, et al.
American Journal of Hematology|September 2, 2022
Retrospective comparison of survival and responses to Fludarabine, Cytarabine, GCSF (FLAG) in combination with gemtuzumab ozogamicin (GO) or Idarubicin (IDA) in patients with newly diagnosed core binding factor (CBF) acute myelogenous leukemia: MD Anderson experience in 174 patientsGautam Borthakur, Farhad Ravandi, Keyur Patel, et al.
The Lancet. Digital Health|February 26, 2022
Development and validation of an ensemble machine learning framework for detection of all-cause advanced hepatic fibrosis: a retrospective cohort studySoren Sabet Sarvestany, Jeffrey C Kwong, Amirhossein Azhie, et al.
American Journal of Hematology|July 21, 2018
Sorafenib Combined with 5-azacytidine in Older Patients with Untreated FLT3-ITD Mutated Acute Myeloid LeukemiaMaro Ohanian, Guillermo Garcia-Manero, Mark Levis, et al.
Frontiers in Oncology|November 16, 2020
Emergence of <i>BCR</i>-<i>ABL1</i> Fusion in AML Post-FLT3 Inhibitor-Based Therapy: A Potentially Targetable Mechanism of Resistance - A Case SeriesAhmad S Alotaibi, Musa Yilmaz, Sanam Loghavi, et al.
Hepatology (Baltimore, Md.)|March 8, 2011
High predictive accuracy of an unbiased proteomic profile for sustained virologic response in chronic hepatitis C patientsKeyur Patel, Joseph E Lucas, J Will Thompson, et al.
American Journal of Hematology|July 4, 2014
Gemtuzumab ozogamicin with fludarabine, cytarabine, and granulocyte colony stimulating factor (FLAG-GO) as front-line regimen in patients with core binding factor acute myelogenous leukemiaGautam Borthakur, Jorge E Cortes, Elihu E Estey, et al.
Pageof 36

Showing results (231-240 of 357) with videos related to

Sort By:
Pageof 36
Gastroenterology|July 13, 2010
An IL28B polymorphism determines treatment response of hepatitis C virus genotype 2 or 3 patients who do not achieve a rapid virologic responseAlessandra Mangia, Alexander J Thompson, Rosanna Santoro, et al.
International Journal of Cardiology|January 3, 2017
Depression and chest pain in patients with coronary artery diseaseSalim S Hayek, Yi-An Ko, Mosaab Awad, et al.
Advances in Wound Care|February 12, 2025
An Open-Label, Interventional, Prospective, Real-World Evidence Study to Evaluate a Multimodal Wound Matrix in Patients with Refractory WoundsYadwinder Dhillon, Gerit Mulder, Keyur Patel, et al.
Aging|September 4, 2023
Availability of living donor optimizes timing of liver transplant in high-risk waitlisted cirrhosis patientsFakhar Ali Qazi Arisar, Shiyi Chen, Catherine Chen, et al.
American Journal of Hematology|September 2, 2022
Retrospective comparison of survival and responses to Fludarabine, Cytarabine, GCSF (FLAG) in combination with gemtuzumab ozogamicin (GO) or Idarubicin (IDA) in patients with newly diagnosed core binding factor (CBF) acute myelogenous leukemia: MD Anderson experience in 174 patientsGautam Borthakur, Farhad Ravandi, Keyur Patel, et al.
The Lancet. Digital Health|February 26, 2022
Development and validation of an ensemble machine learning framework for detection of all-cause advanced hepatic fibrosis: a retrospective cohort studySoren Sabet Sarvestany, Jeffrey C Kwong, Amirhossein Azhie, et al.
American Journal of Hematology|July 21, 2018
Sorafenib Combined with 5-azacytidine in Older Patients with Untreated FLT3-ITD Mutated Acute Myeloid LeukemiaMaro Ohanian, Guillermo Garcia-Manero, Mark Levis, et al.
Frontiers in Oncology|November 16, 2020
Emergence of <i>BCR</i>-<i>ABL1</i> Fusion in AML Post-FLT3 Inhibitor-Based Therapy: A Potentially Targetable Mechanism of Resistance - A Case SeriesAhmad S Alotaibi, Musa Yilmaz, Sanam Loghavi, et al.
Hepatology (Baltimore, Md.)|March 8, 2011
High predictive accuracy of an unbiased proteomic profile for sustained virologic response in chronic hepatitis C patientsKeyur Patel, Joseph E Lucas, J Will Thompson, et al.
American Journal of Hematology|July 4, 2014
Gemtuzumab ozogamicin with fludarabine, cytarabine, and granulocyte colony stimulating factor (FLAG-GO) as front-line regimen in patients with core binding factor acute myelogenous leukemiaGautam Borthakur, Jorge E Cortes, Elihu E Estey, et al.
Pageof 36